Leadiant Biosciences, Inc.
http://leadiant.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Leadiant Biosciences, Inc.
EU Regulatory System Attacked Over Quality Of Approvals
If anyone can throw cold water on the claimed benefits of some of Europe's most recently approved medicines, it’s the international drug bulletin, Prescrire. In an assessment of 108 of the pharma industry’s latest offerings, it gives a cautious welcome to some but says that more than half bring nothing new and others could even be dangerous to patients.
Dutch Hospital Resumes Own Manufacture Of Leadiant’s Costly Drug
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
Leadiant Hit By Second Complaint Over Price Of CTX Drug In Europe
A second complaint has been filed, this time in Belgium, over the “excessive” price hike on Leadiant’s CDCA-containing drug for the rare genetic disorder, CTX.
Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T
Japan approves a large batch of new products including significant first nods globally for AbbVie's antibody for psoriasis and Japan's first gene-based therapy, as well as a pioneering first approval in Asia for a CAR-T drug.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Sigma-Tau HealthScience LLC
- Sigma-Tau PharmaSource Inc.
- Sigma-Tau Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice